Tandem Diabetes Care layoffs, on the record
Every job cut, severance charge and restructuring Tandem Diabetes Care reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 2,400 to approximately 2,500.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 2,400 | December 31, 2023 |
| 10-K for 2024 | approximately 2,650 | December 31, 2024 |
| 10-K for 2025 | approximately 2,500 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryIncurred non-recurring operating lease impairment charges in SG&A from a facilities consolidation, as part of operating efficiency measures.
Word for word“As a part of continued operating efficiency measures in 2023 and 2022, we incurred non-recurring operating lease impairment charges in SG&A of $14.1 million and $12.4 million, respectively, from a facilities consolidation (see Note 6, “Leases”).” 10-K for 2023
Our summaryIncurred employee severance costs.
Word for word“In 2023, we also incurred employee severance costs of $2.7 million.” 10-K for 2023
Our summaryThe filing says it may further restructure its operations, business functions, or assets, and that it has adjusted its strategies before; no specific layoff or severance program is described.
Word for word“We may also decide to further restructure our operations, specific business functions, or assets.” 10-K for 2024
Our summaryThe company recorded one-time restructuring costs in selling, general and administrative expenses for 2025.
Word for word“The increase in SG&A expenses was attributable to one-time charges for non-recurring facility impairment costs of $6.7 million and restructuring costs of $4.2 million.” 10-K for 2025
Our summaryThe company recorded non-recurring restructuring costs in research and development expenses for 2025.
Word for word“The year ended December 31, 2025 included $3.1 million of non-recurring restructuring costs.” 10-K for 2025
Tandem Diabetes Care has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Tandem Diabetes Care’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.